BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults

First and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia or bipolar I or II disorder1 IGALMI demonstrated onset of... | April 6, 2022

Related Keywords

United States ,California ,American ,Helen Ogorman ,Matt Ventimiglia ,John Krystal ,Erik Kopp ,Vimal Mehta ,Robertl Mcneil Jr ,Yale School Of Medicine ,Bioxcel Therapeutics Inc ,Drug Administration ,National Comorbidity Survey Replication ,Department Of Psychiatry ,Journal Of The American Medical Association ,Nasdaq ,National Institute Of Mental Health ,While The Company ,Translational Research ,Globenewswire Inc ,Xcel Therapeutics ,Negative Syndrome Scale Excited Component ,American Medical Association ,Agitation Associated ,Bipolar Disorder ,Orthostatic Hypotension ,Withdrawal Reactions ,That Prolong ,Geriatric Patients ,Prescribing Information ,Private Securities Litigation Reform Act ,Annual Report ,National Institute ,California Medicaid ,Sublingual Dexmedetomidine ,Acute Agitation Associated ,Bioxcel Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,First ,End ,Only ,Rally ,Dissolving ,Sublingual ,Film ,Or ,Moderate ,Dr ,Evere ,Agitation ,N ,Patients ,Ith ,Schizophrenia ,Bipolar , ,Hi ,Isorder1 ,Galmi ,Remonstrated ,Nset Btai Us09075p1057 ,